SynthesisInternational urology and nephrology2025
Circulating levels of visfatin and apelin as biomarkers in chronic kidney disease: a systematic review and meta-analysis.
Synthesis in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Metabolic syndrome and kidney dysfunction: emerging molecular and cellular mechanisms at the metabolic-renal interface.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVisfatin and apelin are adipocytokines, with visfatin linked to vascular dysfunction and apelin involved in renal homeostasis. This systematic review and meta-analysis explored the serum/plasma levels of these adipocytokines in chronic kidney disease (CKD) patients versus healthy controls.
methodRelevant databases, including PubMed, Web of Science, Scopus, and Embase, were searched up to August 2024, and studies reporting visfatin and apelin concentrations in CKD and controls were retrieved for data synthesis. Random-effect meta-analysis was performed to calculate standardized mean differences (SMD) and 95% confidence intervals (CI) for comparison of visfatin and apelin levels in CKD subjects vs. controls.
resultsOut of the 564 studies screened, 14 fulfilled the inclusion criteria, encompassing a collective sample of 1,377 CKD subjects. The CKD group's mean age was 49.51 years (53.50% male), and the control group's mean age was 48.87 years (49.38% male). The meta-analysis indicated a trend of elevated visfatin levels in the CKD group compared to controls (SMD 1.53; 95% CI 0.88-2.19; p < 0.01; I
conclusionOur findings suggest visfatin could be a potential biomarker for CKD, potentially reflecting disease severity; however, apelin levels were not different in CKD and controls. These results may aid in the earlier diagnosis of CKD but need validation through larger, well-structured studies.
Indexed as
Identifiers
40158038What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.